Why Is MADRIGAL PHARMACEUTI (MDGL) Stock Moving Today?

Madrigal Pharmaceuticals Inc. shares are moving higher today, with MDGL up by approximately 3.2% as of 10:00 AM ET. The stock's upward momentum is being driven by a recent announcement regarding the company’s intellectual property portfolio. Specifically, the company secured three new U.S. patents related to its drug candidate, Rezdiffra (resmetirom), which is being developed for the treatment of non-alcoholic steatohepatitis (NASH).

What Happened

According to Business Insider, Madrigal Pharmaceuticals announced the receipt of three new U.S. patents for resmetirom. These include two patents in the F2/F3 stage of development, which will be listed in the FDA’s Orange Book, and a third patent directed to a method of use. The patents are expected to provide additional protection for the company’s key drug candidate and reinforce its competitive position in the NASH treatment space. The article notes that the patents are a significant development for the company’s long-term strategy and could support future commercialization efforts.

What The Data Shows

The AI sentiment score for recent coverage of MDGL stands at 67 out of 100, indicating a positive tone. There have been no insider purchases in the last 90 days, while three insider sales have occurred, totaling $3.9 million, with the most recent transaction reported on June 1, 2026. No unusual options activity or social media chatter was reported as material to the stock’s current movement.

What To Watch

Madrigal Pharmaceuticals does not have an upcoming earnings date scheduled in the next 30 days. Investors may want to monitor the broader market reaction to the patent news and how it influences coverage and sentiment in the coming days.